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Dear Editor,
Predicting recovery of renal function
in patients with acute kidney injury
(AKI) supported with renal replace-
ment therapy (RRT) is one of the top
ten questions in the field of current
AKI research. However, defining
renal recovery and accordingly the
best time for discontinuation of RRT
is difficult, as reliable biomarkers are
lacking.
The Beginning and Ending Sup-
portive Therapy for the Kidney
(BEST Kidney) study identified urine
production ([500 mL/24 h) as the
best predictor for successful discon-
tinuation of RRT [area under the curve
(AUC) 0.81] in contrast to serum
creatinine (SCr, AUC 0.64); however,
its predictive value is severely con-
founded by the use of diuretics [1].
Neutrophil gelatinase-associated
lipocalin (NGAL), a 25-kDa protein
involved in iron transportation, is a
potential tool for determination of
initiation of RRT [2, 3]. However,
once a patient is initiated on RRT, it
remains to be elucidated how plasma
NGAL concentrations will change.
To determine plasma NGAL
clearance and sieving coefficient
(SQ) during continuous RRT
(CRRT), we measured prefilter and
effluent NGAL concentrations in
three subjects after informed consent
was obtained. Patients were hemofil-
tered with zero fluid balance, 2 L
postdilution mode in continuous
veno-venous hemofiltration. Blood
flow was set at 200 mL/min, and
regional citrate anticoagulation was
used. The filters were ethylene oxide
(ETO)-sterilized Aquamax HF 19
with an in vitro cutoff point of
55 kDa.
NGAL levels were measured using
a research-based enzyme-linked
immunosorbent assay with detection
limit of 10–4,000 ng/mL. NGAL
clearance per minute was estimated
using the assumed stable plasma
concentrations during CRRT over the
first 12 h and the calculated amount
Fig. 1 Temporal patterns of the prefilter plasma and effluent NGAL concentrations
(ng/ml) in hours after initiation of continuous veno-venous renal replacement therapy in
three individuals with anuric AKI
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of NGAL present in the total effluent.
SQ was calculated by dividing the
NGAL effluent concentration by the
NGAL prefilter plasma concentration.
Three male anuric patients were
studied (age 40–64 years). Their
admission diagnoses were hemor-
rhagic shock, cardiopulmonary
resuscitation, and multitrauma. Base-
line SCr values were 0.57, 0.66, and
0.68 mg/dL, with SCr at time of CRRT
initiation of 3.7, 9.7, and 12.3 mg/dL.
Estimated median (standard deviation,
SD) plasma NGAL clearance was 4.8
(1.89) mL/min with median (SD) SQ
of 0.147 (0.04). The prefilter and
effluent NGAL concentrations are
plotted against time in Fig. 1.
Normally, plasma NGAL is
cleared through glomerular filtration
and entirely processed by proximal
tubular cells [4]. However, in case of
AKI, plasma concentrations rise
quickly, even when estimated glo-
merular filtration rate (eGFR) is still
normal, and tend to decrease quickly
when the injurious event subsides [5].
Therefore, NGAL might have poten-
tial to be an early indicator of renal
recovery in critically ill patients sup-
ported by RRT.
Our results suggest that plasma
NGAL is hardly cleared during con-
tinuous veno-venous hemofiltration.
A possible explanation lies in the fact
that larger serum proteins effectively
lower the passage of small proteins by
forming a gel layer over the mem-
brane pores.
In conclusion, we have shown that
CRRT does not substantially influ-
ence plasma NGAL concentration
and therefore does not need to be
taken into account when kinetics of
plasma NGAL levels are used as an
indicator for persistent renal injury or
renal recovery in hemofiltered criti-
cally ill patients.
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